NDANASALSPRAY, METERED
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
GIMOTI (metoclopramide hydrochloride) by Pfizer is gastric, biliary, or pancreatic secretions. First approved in 2020.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GIMOTI is a nasal spray formulation of metoclopramide hydrochloride, a prokinetic agent approved in 2020 by Pfizer. It treats gastroesophageal reflux disease and diabetic gastroparesis by enhancing gastric contractions and accelerating gastric emptying. The drug works by sensitizing tissues to acetylcholine, increasing lower esophageal sphincter tone, and promoting duodenal and jejunal peristalsis.
$0.003BPart D
Peak12.0 years to LOEProduct is in peak lifecycle stage with modest Medicare utilization (1,457 Part D claims in 2023), suggesting a niche market with stable but limited commercial opportunity for brand team expansion.
Mechanism of Action
gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize tissues to the action of acetylcholine. The effect of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GIMOTI offers exposure to a niche, specialty gastroenterology product with unique formulation innovation but limited scale compared to blockbuster assets. Career progression depends heavily on commercial execution in a zero-competitor market segment and navigating the safety profile challenges inherent to metoclopramide.
Worked on GIMOTI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.